Jefferies & Co downgrades Gilead Sciences (GILD) to Hold
More News related to GILD
- ACT Announces Partnership With Gilead Sciences Inc.
- David Moenning’s Daily State of the Markets: 6/26
- Gilead (GILD) Announces European CHMP Adopts Positive Opinion for Aztreonam Lysine
- Gilead Sciences (GILD) Announces European CHMP Positive Opinin for Aztreonam Lysine
- European CHMP Adopts Positive Opinion for Aztreonam Lysine
Jefferies & Co downgrades Gilead Sciences (Nasdaq: GILD) from Buy to Hold. Price target $56.
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need.
Related Categories
DowngradesStocks Mentioned
-0.93Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
